Location:MT, US
Speaker:Brian Campion, Ph.D.
Title:VP Corporate Development
Primary Industry:Pharma & Biotech
Executive Summary:SpeciGen employs protein cage nanotechnology for drug delivery, initially focused on making approved chemotherapeutic drugs safer and more effective. In 2007, the company will perform pre-clinical studies in animal models of disease to prove safety and efficacy prior to proceeding to human clinical trials. In preliminary in vitro and in vivo studies, the company has shown the ability to sequester chemotherapeutic drugs inside protein cages that are targeted to cancer cells by peptides attached to the outside of the cages. A variety of methods to release the drug have been employed. The goal of targeted and controlled drug delivery and release is lowered toxicity and increased efficacy in a variety of refractory, life-threatening cancers (breast, lung and colorectal). SpeciGen\'s technology is being developed in research collaborations with Montana State University, the NIH, Stanford School of Medicine, the Burnham Institute and Calvert Research Institute. The focus of these collaborations include diagnostic imaging and therapy of cancer, cardiovascualr and infectious diseases. The company is seeking investors to participate in a Series A Preferred Stock offering to help fund the developmental studies leading to human clinical trials. Inquiries about licensing product candidates are invited.
Venture is:A-Round


Corporate Presentations:

  • Air Products
  • BASF
  • Eastman Kodak Company
  • Genzyme
  • Goodrich
  • Hewlett-Packard
  • Honda
  • Medtronic
  • Merck
  • Sanyo

Reserved Presentations:

  • ExxonMobil
  • IBM

Partnering Events:
(full access included)

Platinum Sponsor

University of Hawaii

Press Sponsor

Business Wire

Commercialization Partner



Invest Australia AzTE Technology Enterprises

Media Sponsors

(joint with Nanotech 2007) Nature
Red Herring

Supporting Organizations

Boston University
Midwest Research University Network


“A major challenge for both the technology and the financial communities is finding a forum in which all parties can interact and explore possibilities for future innovation. TechConnect was created to fill this void, bringing both sides together under one roof into a setting that ultimately will help significant ground-breaking concepts come to life.”
Matthew Laudon, Co-Founder and Director of TechConnect